Literature DB >> 6481185

Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.

C H Hatheway, J D Snyder, J E Seals, T A Edell, G E Lewis.   

Abstract

Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of 1 X 10(8), 9 X 10(7), and 6 X 10(6) 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2-4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10-1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481185     DOI: 10.1093/infdis/150.3.407

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

2.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel.

Authors:  Audrey Fischer; Yuya Nakai; Lisa M Eubanks; Colin M Clancy; William H Tepp; Sabine Pellett; Tobin J Dickerson; Eric A Johnson; Kim D Janda; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

3.  Wound botulism from heroin skin popping.

Authors:  Larry E Davis; Molly K King
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

4.  Wound botulism complicating internal fixation of a complex radial fracture.

Authors:  Steve M Taylor; Cameron R Wolfe; Terry C Dixon; David S Ruch; Gary M Cox
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

5.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Authors:  Susan E Maslanka; Carolina Lúquez; Janet K Dykes; William H Tepp; Christina L Pier; Sabine Pellett; Brian H Raphael; Suzanne R Kalb; John R Barr; Agam Rao; Eric A Johnson
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

6.  Kinetics study of immunological response to Clostridium botulinum toxin.

Authors:  M Dezfulian; R A Bitar; J G Bartlett
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

7.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

8.  Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.

Authors:  Yuan-Ping Pang; Jon Davis; Shaohua Wang; Jewn Giew Park; Madhusoodana P Nambiar; James J Schmidt; Charles B Millard
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A.

Authors:  Julie Prigent; Christelle Mazuet; Didier Boquet; Patricia Lamourette; Hervé Volland; Michel R Popoff; Christophe Créminon; Stéphanie Simon
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

10.  Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.

Authors:  Jin Sook Yoon; Jae Chan Kim; Sang Yeul Lee
Journal:  Korean J Ophthalmol       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.